Цель.Цель: Сравнить влияние монотерапии аторвастатином и комбинированного применения аторвастатина с курцетином (смесь биофлавоноидов куркумина и кверцетина) на липидный спектр и биомаркеры воспаления у больных нестабильной стенокардией, после COVID-19 («Долгий COVID»).Материал и методы.Материал и методы. Проведено открытое простое сравнительное рандомизированное исследование 186 больных с диагнозом: ИБС. Прогрессирующая стенокардия напряжения, в том числе 77 (I группа) пациентов, у которых дестабилизация стенокардии возникла вследствие перенесенного COVID-19 в течение 4-8 недель до включения в исследование, и 109 пациентов (II группа), у которых дестабилизация не имела связи с перенесенной инфекцией.Результаты.Результаты: В I группе уровень вчС-реактивного белка [5,4 (2,06-7,4) г/л и IL-6 8,6 (5,4-10,3) пг/мл] был выше (Р < 0,05), чем во II группе больных [3,8 (1,2-4,0) г/л и 6,9 (2,2-10,2) пг/мл], соответственно. В I подгруппе больных, перенесших COVID-19, монотерапия аторвастатином (n = 43) не оказала значительного эффекта при двухмесячном лечении, тогда как во II подгруппе комбинированное применение аторвастатина с курцетином (n = 34) в течение 2 месяцев снизило уровень вчСРБ на 49,0[%] (Р < 0,05) и IL-6 на 40,0[%] (Р < 0,05).Заключение.Заключение. У больных нестабильной стенокардией после COVID-19 комбинированное лечение аторвастатином с курцетином снижало концентрацию биомаркеров воспаления в отличие от монотерапии аторвастатином.
Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265–1273.
Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponinpositive COVID-19 patients assessed by cardiovascular magnetic resonance. European Heart Journal. (2021) 1866–1878. doi: 10.3410/f.739571449.793583038.
DOI: 10.3410/f.739571449.793583038
Thornton GD, Shetye A, Knight DS, Knott K., et al. Myocardial Perfusion Imaging After Severe COVID-19 Infection Demonstrates Regional Ischemia Rather Than Global Blood Flow Reduction. Front Cardiovasc Med 2021 Dec 7;8:764599. doi: 10.3389/fcvm.2021.764599. eCollection 2021..
DOI: 10.3389/fcvm.2021.764599. eCollection 2021
Venkatesan, P. NICE guideline on long COVID – The Lancet Respiratory Medicine. Lancet Respir. Med. 2021;9(2):129. doi: 10.1016/s2213-2600(21)00031-x.
DOI: 10.1016/s2213-2600(21)00031-x
Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z.
DOI: 10.1038/s41591-021-01283-z
Datta, S. D., Talwar, A. & Lee, J. T. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: Illness beyond acute infection and public health implications. JAMA 2020 Dec 8;324(22):2251-2252. doi: 10.1001/jama.2020.22717.
DOI: 10.1001/jama.2020.22717
Greenhalgh, T., Knight, M., Buxton, M. & Husain, L. Management of post-acute Covid-19 in primary care. BMJ 2020 Aug 11;370:m3026. doi: 10.1136/bmj.m3026.
DOI: 10.1136/bmj.m3026
An Y-W, Song S, Li W-X, Chen Y-X et al. Liver function recovery of COVID-19 patients after discharge, a follow-up study. Int J Med Sci 18: 176–186, 2021. doi: 10.7150/ijms.50691.
DOI: 10.7150/ijms.50691
Wang Y, Liu S, Liu H, Li W et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 73: 807-816, 2020. doi: 10.1016/j.jhep.2020.05.002.
DOI: 10.1016/j.jhep.2020.05.002
Spearman CW, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: a 2021 update. Liver Int 41: 1988–1998, 2021. doi: 10.1111/liv.14984.
DOI: 10.1111/liv.14984
Amar D. Desai,* Michael Lavelle,* Brian C. Boursiquot, and Elaine Y. Wan. Long-term complications of COVID-19. Am J Physiol Cell Physiol 2022 Jan 1;322(1):C1-C11. doi: 10.1152/ajpcell.00375.2021.
DOI: 10.1152/ajpcell.00375.2021
Raman B, Bluemke DA, Lüscher TF, and Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus European Heart Journal. 2022 Mar 14;43(11):1157-1172. doi: 10.1093/eurheartj/ehac031.
DOI: 10.1093/eurheartj/ehac031
Di Filippo L, De Lorenzo R, D’Amico M, Sofia V et al. COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: a post-hoc analysis of a prospective cohort study. Clin Nutr 2021 Apr;40(4):2420-2426. doi: 10.1016/j.clnu.2020.10.043.
DOI: 10.1016/j.clnu.2020.10.043
Morley JE, Kalantar-Zadeh K, Anker SD. COVID-19: a major cause of cachexia and sarcopenia? J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):863-865. doi: 10.1002/jcsm.12589.
DOI: 10.1002/jcsm.12589
Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms. J Card Fail. 2020. doi: 10.1016/j.cardfail.2020.04.009.
DOI: 10.1016/j.cardfail.2020.04.009
National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. 2020. Available online: https://www.nice.org.uk/guidance/ng188/chapter/context#post-covid-19-syndrome (accessed on 28 January 2021).https://www.nice.org.uk/guidance/ng188/chapter/context#post-covid-19-syndrome
Toraih, EA, Elshazli, RM, Hussein, MH, Elgaml, A, Amin, M, El-Mowafy, M, et al.. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: a meta-regression and decision tree analysis. J Med Virol 2020 Nov;92(11):2473-2488. doi: 10.1002/jmv.26166.
DOI: 10.1002/jmv.26166
Guzik TJ, Mohiddin SA, Dimarco A, Patel V, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 116: 1666–1687, 2020. doi:10.1093/cvr/cvaa106.
DOI: 10.1093/cvr/cvaa106
Chou CH, Hung CS, Liao CW, Wei LH, Chen CW, Shun CT, Wen WF, Wan CH, Wu XM, Chang YY, Wu VC, Wu KD, Lin YH, TAIPAI Study Group. IL-6 transsignalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res 2018; 114:690–702.
Watson C, Whittaker S, Smith N, Vora AJ, Dumonde DC, Brown KA. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin Exp Immunol 1996;105:112–119.
van Tits LJ, Stienstra R, van Lent PL, Netea MG, Joosten LA, Stalenhoef AF. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis 2011;214:345–349.
Deftereos SG, Giannopoulos G, Vrachatis DA, et al Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136.
DOI: 10.1001/jamanetworkopen.2020.13136
Pourdowlat G, Saghafi F, Mozafari A, Sahebnasagh A et al Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial. Phytotherapy Research. 2022 Feb;36(2):891-898. doi: 10.1002/ptr.7319.
DOI: 10.1002/ptr.7319
COVID-19 Scientific Advisory Group Rapid Evidence Report Colchicine for the treatment of COVID-19, February 23, 2021
Zhen-Zhen Wang ZZ, Li K, Maskey AR, Huang W, Toutov AA. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study. The FASEB Journal. 2021;35:e21360.
Zhang BY, Chen M, Chen XC, Cao K, You Y et al. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19 BJS, 2021, 108, e9–e11
Bernini R and Velotti F. Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19. Molecules 2021 Sep 25;26(19):5803. doi: 10.3390/molecules26195803.
DOI: 10.3390/molecules26195803
Saeedi-Boroujeni A and Mahmoudian-Sani MR. Anti-inflammatory potential of Quercetin in COVID-19 treatment. Journal of Inflammation. 2021 Jan 28;18(1):3. doi: 10.1186/s12950-021-00268-6.
DOI: 10.1186/s12950-021-00268-6
Rattis BA, Ramos SG and Celes MR. Curcumin as a potencial treatment for COVID-19. Frontiers in pharmacology, 2021 May, v. 12, article 675287
Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F, Guest PC et al. Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials. Nutrients. 2022 Jan 7;14(2):256. doi: 10.3390/nu14020256.
DOI: 10.3390/nu14020256
Ruscica M., Penson P.E., Ferri N., Zhisheng J., Zirlik A. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular diseases. 2021 Jul-Aug;67:40-52. doi: 10.1016/j.pcad.2021.06.010.
DOI: 10.1016/j.pcad.2021.06.010
Heeba GH, Mahmoud ME, El Hanafy AA. Anti-inflammatory potential of curcumin and quercetin in rats: role of oxidative stress, heme oxygenase-1 and TNF-α. Toxicol Ind Health. 2014 Jul;30(6):551-60. doi: 10.1177/0748233712462444. Epub 2012 Sep 28..
DOI: 10.1177/0748233712462444. Epub 2012 Sep 28
Güran M, Şanlıtürk G, Kerküklü NR, Altundağ EM, Süha Yalçın A. Combined effects of quercetin and curcumin on anti-inflammatory and antimicrobial parameters in vitro. Eur J Pharmacol. 2019 Sep 15;859:172486. doi: 10.1016/j.ejphar.2019.172486. Epub 2019 Jun 25..
DOI: 10.1016/j.ejphar.2019.172486. Epub 2019 Jun 25